Replies to post #119753 on Biotech Values

[go seek]

more buying, than selling...

The IDIX run is hard to figure (expect you sense that here)... but what appears to be a good short, may bite you in the butt.

I would not be long or short.

[DewDiligence]

anyone have a theory for what is behind the run?

Possibly a buyout. IDIX no longer has the scale to be a standalone drug-discovery company in the antiviral arena, so it would make sense for the company to be sold.

The founder and ex-CEO, JP Sommadossi, was never replaced; instead, the CFO simply moved into the corner office. This is exactly what happened at CEPH when the founder and CEO, Frank Baldino, died in Dec 2010; a few months later, the company was sold.